secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010101
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity
--------------------------------------------------------------------------------

- Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
- Ended Q1 with $25.2M cash; subsequent public offering netted $16.1M; combined with earlier offerings total ~$46.7M raised.
- Partnered with major health system for EsoGuard testing; NCI study supports expanded indication without GERD, increasing market 70%.
- Cash-pay and employer channels expected to start contractually-guaranteed revenue in 2H25.
- Proforma cash over $40M at Q1 end; runway extended past key Medicare and other reimbursement milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000164117225010101/0001641172-25-010101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000164117225010101/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer